Abstract:Introduction: Nitroimidazole (azomycin) derivatives labeled with radioisotopes have been developed as cancer imaging and radiotherapeutic agents based on the oncological hypoxic mechanism. By attaching nitroimidazole core with different functional groups, we synthesized new nitroimidazole derivatives and evaluated their potentiality as tumor imaging agents.Methods: Starting with commercially available 2-nitroimidazole, 2-fluoro-N-(2-(2-nitro-1H-imidazol-1-yl)ethyl)acetamide (NEFA, [F-19]7) and 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 2-fluoroacetate (NEFT, [F-19]8), as well as radiolabeling precursors, the bromo-substituted analogs were quickly synthesized through a three-step synthetic pathway. The precursors were radiolabeled with [F-18]F-/18-crown-6/KHCO3 in dimethyl sulfoxide at 90 degrees C for 10 min followed by purification with an Oasis HLB cartridge. Biodistribution studies were carried out in EMT-6 tumor-bearing mice. The uptake (%ID/g) in tumors and normal tissues were measured at 30 min postinjection. Liquid chromatography-electrospray ionization mass spectrometry (LC/MS) was used to distinguish metabolites from parent drugs in urine and plasma of rat injected with "cold" NEFA ([F-19]7) and NEFT ([F-19]8).Results: Two radiotracers, [F-18]NEFA ([F-18]7) and [F-18]NEFT ([F-18]8), were prepared with average yields of 6%-7% and 9%-10% (not decay corrected). Radiochemical purity for both tracers was >95% as determined by HPLC. Biodistribution studies in EMT-6 tumor-bearing mice indicated that the tumor to blood and tumor to liver ratios of both [F-18]7 (0.96, 0.61) and [F-18]8 (0.98, 1.10) at 30 min were higher than those observed for [F-18]FMISO (1) (0.91, 0.59), a well-investigated azomycin-type hypoxia radiotracer. Liquid chromatography-electrospray ionization mass spectrometry analysis demonstrated that fluoroacetate was the main in vivo metabolite for both NEFA ([F-19]7) and NEFT ([F-19]8).Conclusions: In this research, two new fluorine-18 labeled 2-nitroimidazole derivatives, [F-18]7 and [F-18]8, both of which containing in vivo hydrolyzable group, were successfully prepared. Further biological evaluations are warranted to investigate their potential as PET radioligands for imaging tumor. (C) 2011 Elsevier Inc. All rights reserved.

18F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging

Synthesis and Biological Evaluation of Novel F-18 Labeled Pyrazolo[1,5-A]pyrimidine Derivatives: Potential PET Imaging Agents for Tumor Detection.

18F-labeled Pyrazolo[1,5-a]pyrimidine Derivatives: Synthesis from 2,4-Dinitrobenzamide and Tosylate Precursors and Comparative Biological Evaluation for Tumor Imaging with Positron Emission Tomography

F-18-Labeled Pyrazolo[1,5-A]Pyrimidine Derivatives: Synthesis From 2,4-Dinitrobenzamide And Tosylate Precursors And Comparative Biological Evaluation For Tumor Imaging With Positron Emission Tomography

Synthesis and Evaluation of Novel F-18 Labeled 4-Aminoquinazoline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Methodological Progress of 18 F-labeled Aromatic PET Radiotracers

Synthesis of 2-R 1 -2-(4-(2-fluoroethoxy)benzamido)acetate As Potential PET Imaging Agents

Synthesis and Evaluation of Novel F-18 Labeled Fluoroarylvaline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Evaluation of 18 F-labeled Icotinib Derivatives As Potential PET Agents for Tumor Imaging

Synthesis and Evaluation of Novel F-18-Labeled Pyrimidine Derivatives: Potential Fak Inhibitors and Pet Imaging Agents for Cancer Detection

Synthesis and Evaluation of Novel ¹⁸F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives As Ligands for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques.

Novel ¹⁸F-labeled dibenzylideneacetone derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.

Difluorocarbene-enabled synthesis of 18 F-radiotracers in positron emission tomography

Research progress of 18F labeled small molecule positron emission tomography (PET) imaging agents

Synthesis and Evaluation of Two Novel 2-Nitroimidazole Derivatives As Potential Pet Radioligands for Tumor Imaging

Synthesis and Biological Evaluation of 3-O-(2-18 F-fluoroethyl)-L-DOPA As A Potential PET Agent for Tumor Imaging

In Vivo Ester Hydrolysis As a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.

Synthesis and Biological Evaluation of 7-(2-chlorophenylamino)-5-((2- [18F]fluoro-Ethyoxy)methyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile As PET Tumor Imaging Agent

Preliminary Characterization and in Vivo Studies of Structurally Identical 18F- and 125I-Labeled Benzyloxybenzenes for PET/SPECT Imaging of Β-Amyloid Plaques

Synthesis and Evaluation of Novel 18f‐labeled Quinazoline Derivatives with Low Lipophilicity for Tumor PET Imaging

Novel 18F-Labeled Benzimidazolone-Based Radioligands As Highly Selective Sigma-2 Receptor Probes for Tumor Imaging